Table 2.
JCV load and STRATIFY JCV® of RRSM patients at baseline (t0)
| Pt (n) | Pt JCV DNA+ (n)b | Pt JCV DNA− (n)b | Urine | Plasma | PBMC | |||
|---|---|---|---|---|---|---|---|---|
| JCV+/JCV− | log10 gEq/mL (range)c | JCV+/JCV− | log10 gEq/mL (range)c | JCV+/JCV− | log10 gEq/106 c (range)c | |||
| STRATIFY JCV®a positive | ||||||||
| 4 | 1 | 3 | 0/4 | – | 1/3 | 2.84 | 1/3 | 2.07 |
| STRATIFY JCV®a negative | ||||||||
| 18 | 7 | 11 | 4/14 | 4.38 (3.48–4.58) | 2/16 | 3.02 (2.70–3.20) | 2/16 | 3.42 (1.95–3.72) |
| Total (n) | 8/22 | 14/22 | 4/18 | 4.38 (3.48–4.58) | 3/19 | 2.84 (2.70–3.20) | 3/19 | 2.07 (1.95–3.72) |
n number of patients, Pt patients
aSTRATIFY JCV®: two-step virus-like particle-based enzyme-linked immunosorbent assay (ELISA) was performed at t0, to detect specific anti-JC virus antibodies in serum
bPt JCV DNA+ and Pt JCV DNA−: number of patients with or without JCV DNA in at least 1 sample of plasma and/or PBMCs and/or urine
cJCV load values were expressed as median (range) of log10 genome equivalent (gEq)/mL in urine and in plasma, and as median (range) log10 gEq/106 cells in PBMCs (gEq/106 c)